HWH486 / Humanwell Healthcare - LARVOL DELTA

A multicenter, randomized, double-blind, placebo-controlled Phase IIa study to explore the efficacy, safety, and pharmacokinetic profile of HWH486 in adults with chronic spontaneous urticaria (ChiCTR) - P2 | N=120 | Recruiting | Sponsor: West China Hospital,Sichuan University; Hubei Bio-pharmarceutical Industrial Technological Institute INC.

New P2 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Hubei Biological Medicine Industrial Technology Institute Co., Ltd.

New P2 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study. (PubMed, Int Immunopharmacol) - "HWH486 is well tolerated and safe in healthy adults, in whom it can strongly bind Bruton's tyrosine kinase. These findings justify clinical studies of HWH486 efficacy against autoimmune diseases."

Clinical • Journal • P1 data • PK/PD data • Chronic Spontaneous Urticaria • Dermatology • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Urticaria